OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.
GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.
To read the full press release, please follow this link.
Related resources
Six Things to Consider When Protecting the Design of Your Food and Drink Product
When it comes to protecting the logo, branding and packaging of your food and drink product, often people...
Key Tips for Patenting Polymers
Synthetic polymers are a broad and versatile class of materials that are crucial to many areas of technology. ...
Closed Loop Medicine Raises £2.1M Pre-Series A
GJE client Closed Loop Medicine raised £2.1M in venture capital funding. The raise for the Cambridge-based health tech start-up was from Longwall Ventures Partners amongst other investment groups. Closed Loop Medicine is a start-up that helps doctors and healthcare providers deliver personalised treatment regimens by combining proven drug treatments with digital therapeutics. The funding will support the development of a...